- Home
- ZENV vs QNRX Comparison
ZENV vs QNRX Comparison
Compare ZENV & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | QNRX |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 14.5M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZENV | QNRX |
|---|---|---|
| Price | $0.44 | $8.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 568.0K | 21.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.21 |
| 52 Week High | $2.16 | $41.80 |
Technical Indicators
Market Signals| Indicator | ZENV | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 45.76 |
| Support Level | $0.25 | $8.03 |
| Resistance Level | $1.00 | $10.05 |
| Average True Range (ATR) | 0.07 | 0.60 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 27.05 | 25.13 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.